GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap

GlaxoSmithKline R&D chief Hal Barron has tossed a lineup of COPD drugs out of the pipeline in the latest shift away from respiratory diseases. And there was a cancer drug as well as an HIV program in the mix of the nixed.